Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva - Full Text View

Sponsors and Collaborators:	Gynecologic Oncology Group National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00003325

Purpose

RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva.

PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.

Condition	Intervention	Phase
Vulvar Cancer	Drug: isosulfan blue Procedure: conventional surgery Procedure: sentinel lymph node biopsy	Phase III

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva

Resource links provided by NLM:

MedlinePlus related topics: Cancer Vulvar Cancer

Drug Information available for: Iso-sulfan blue

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Disease status [ Designated as safety issue: No ]
Tumor characteristics (e.g., stage, clinical tumor size, status of the capillary/lymphatic spaces, and histologic type of tumor) [ Designated as safety issue: No ]
Host characteristics (e.g., age and performance status) [ Designated as safety issue: No ]
Adverse effects of the mapping procedure and dissection (i.e., frequency and severity) [ Designated as safety issue: Yes ]

Estimated Enrollment:	630
Study Start Date:	December 1999
Estimated Primary Completion Date:	November 2001 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Determine the negative predictive value of a negative sentinel lymph node in patients with invasive squamous cell carcinoma of the vulva.
Determine the location of the sentinel node in these patients.

OUTLINE: Patients receive injection(s) of isosulfan blue into the dermis at the junction of the tumor and normal vulvar skin. Once the afferent lymphatic channel and sentinel node have been identified, patients undergo unilateral or bilateral inguinal-femoral lymphadenectomy followed by resection of the primary tumor with adequate margins. Preoperative lymphoscintigraphy is also performed.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter or until recurrence.

PROJECTED ACCRUAL: A total of 40-630 patients will be accrued for this study within 2-6 years.

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed invasive squamous cell carcinoma of the vulva that is greater than 1 mm in thickness as measured from the nearest rete peg
- Tumor size must be 2-6 cm
- No recurrent disease
Prior excision of the primary disease or a history of carcinoma in situ of the vulva allowed
No tumor extending into the urethra, anus, vagina, rectum, or bladder
No grossly suspicious or inflamed groin nodes on physical exam
No grossly infected primary tumors

PATIENT CHARACTERISTICS:

Age:

Any age

Performance status:

GOG 0-3

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No other invasive malignancy within the past 5 years except non-melanomatous skin cancer
No known hypersensitivity to phenylethane compounds

PRIOR CONCURRENT THERAPY:

No prior cancer therapy that contraindicates therapy in this study

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

See Disease Characteristics
No prior groin dissection

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003325

Show 72 Study Locations

Sponsors and Collaborators

Gynecologic Oncology Group

National Cancer Institute (NCI)

Investigators

Study Chair:	Charles Levenback, MD	M.D. Anderson Cancer Center
Investigator:	Benjamin E. Greer, MD	Fred Hutchinson Cancer Research Center

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Levenback CF, Tian C, Coleman RL, et al.: Sentinel node (SN) biopsy in patients with vulvar cancer: A Gynecologic Oncology Group (GOG) study. [Abstract] J Clin Oncol 27 (Suppl 15): A-5505, 2009.

Responsible Party:	Gynecologic Oncology Group ( Philip J. DiSaia )
Study ID Numbers:	CDR0000066277, GOG-173
Study First Received:	November 1, 1999
Last Updated:	July 20, 2009
ClinicalTrials.gov Identifier:	NCT00003325 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

stage I vulvar cancer
stage II vulvar cancer
squamous cell carcinoma of the vulva

Study placed in the following topic categories:

Genital Diseases, Female
Vulvar Neoplasms
Vulvar Cancer
Epidermoid Carcinoma
Genital Neoplasms, Female

Urogenital Neoplasms
Squamous Cell Carcinoma
Carcinoma, Squamous Cell
Vulvar Diseases
Carcinoma

Additional relevant MeSH terms:

Genital Diseases, Female
Neoplasms
Neoplasms by Site
Vulvar Neoplasms

Genital Neoplasms, Female
Urogenital Neoplasms
Vulvar Diseases

ClinicalTrials.gov processed this record on September 01, 2009